1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

EC Approves Extended Invokana Indication On Renal Outcomes In DKD

First SGLT2 Inhibitor In Europe To Gain Extended Indication

 
• By John Davis

Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.    

Back_Pain
• Source: Shutterstock

Janssen Pharmaceutical Cos./Mundipharma International Corp. Ltd.’s SGLT2 inhibitor, Invokana (canagliflozin), has become the first drug in nearly 20 years to have its indications in Europe extended to include renal outcomes data from a Phase III study in patients with diabetic kidney disease (DKD) and type 2 diabetes.

The European Commission’s approval, announced by Mundipharma on 1 July, follows a positive recommendation from the EMA’s CHMP in May...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.